DE122009000037I2 - Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis - Google Patents

Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Info

Publication number
DE122009000037I2
DE122009000037I2 DE122009000037C DE122009000037C DE122009000037I2 DE 122009000037 I2 DE122009000037 I2 DE 122009000037I2 DE 122009000037 C DE122009000037 C DE 122009000037C DE 122009000037 C DE122009000037 C DE 122009000037C DE 122009000037 I2 DE122009000037 I2 DE 122009000037I2
Authority
DE
Germany
Prior art keywords
enzephalitis
japanese
analyzed
virus
vero cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE122009000037C
Other languages
English (en)
Other versions
DE122009000037I1 (de
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CJ Corp
Walter Reed Army Institute of Research
Original Assignee
CJ Corp
Walter Reed Army Institute of Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CJ Corp, Walter Reed Army Institute of Research filed Critical CJ Corp
Publication of DE122009000037I1 publication Critical patent/DE122009000037I1/de
Publication of DE122009000037I2 publication Critical patent/DE122009000037I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE122009000037C 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis Active DE122009000037I2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR19970042002 1997-08-28
KR19970042001 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine
DE69837211T DE69837211T2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Publications (2)

Publication Number Publication Date
DE122009000037I1 DE122009000037I1 (de) 2009-11-05
DE122009000037I2 true DE122009000037I2 (de) 2011-06-16

Family

ID=26633032

Family Applications (2)

Application Number Title Priority Date Filing Date
DE122009000037C Active DE122009000037I2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis
DE69837211T Expired - Lifetime DE69837211T2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69837211T Expired - Lifetime DE69837211T2 (de) 1997-08-28 1998-08-25 Ein an vero-zellen angepasstes abgeschwächtes japanische enzephalitis virus und ein impfstoff gegen japanische enzephalitis

Country Status (15)

Country Link
US (1) US6309650B1 (de)
EP (2) EP1604685B1 (de)
JP (1) JP4161017B2 (de)
KR (1) KR100314404B1 (de)
CN (1) CN1142271C (de)
AU (1) AU748730B2 (de)
CA (1) CA2301000C (de)
DE (2) DE122009000037I2 (de)
DK (2) DK1025209T3 (de)
ES (2) ES2281929T3 (de)
FR (1) FR09C0037I2 (de)
MY (1) MY129773A (de)
NL (1) NL300391I2 (de)
NZ (1) NZ503522A (de)
WO (1) WO1999011762A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
CN1160454C (zh) * 1998-10-05 2004-08-04 财团法人阪大微生物病研究会 用于抗日本脑炎病毒感染的灭活疫苗的增强免疫原及其生产方法
WO2000065032A1 (en) * 1999-04-22 2000-11-02 United States Department Of Agriculture Porcine reproductive and respiratory syndrome vaccine, based on isolate ja-142
AU4472801A (en) * 2000-04-07 2001-10-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese B encephalitis vaccine and process for producing the same
CN1253220C (zh) * 2001-06-29 2006-04-26 贝克顿迪肯森公司 通过微管在真皮内输入疫苗和基因治疗剂
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
EP1718738A2 (de) * 2004-02-23 2006-11-08 Crucell Holland B.V. Verfahren zur reinigung von viren
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈－丁二烯－苯乙烯共聚物及其回收方法
CA2602944C (en) * 2005-04-11 2015-08-11 Crucell Holland B.V. Virus purification using ultrafiltration
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
CA2710611C (en) * 2007-12-26 2016-12-20 The Kitasato Institute Method of producing japanese encephalitis vaccine stably storable over long time and use of the vaccine
EP2298344B1 (de) * 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Verwendung von inaktivierten japanischen enzephalitis-virus-partikel als adjuvans
KR101622738B1 (ko) * 2008-07-30 2016-05-19 히사미쓰 세이야꾸 가부시키가이샤 마이크로니들 디바이스 및 마이크로니들 디바이스에 의한 일본 뇌염 바이러스 항원의 주효성을 상승시키는 방법
KR20120027381A (ko) * 2009-05-25 2012-03-21 파나세아 바이오테크 리미티드 일본뇌염 백신 및 그것의 제조 방법
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
SI3106176T1 (en) 2011-12-06 2018-04-30 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
IN2013CH04135A (de) * 2013-09-14 2015-08-14 Bharat Biotech Int Ltd
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
BR112018012873A2 (pt) 2015-12-23 2018-12-04 Valneva Austria Gmbh vacina de vírus zika
CA3010049C (en) * 2016-01-15 2021-10-12 The Chemo-Sero-Therapeutic Research Institute Vaccine containing immobilized virus particles
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
US11484587B2 (en) 2017-09-21 2022-11-01 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic Chikungunya virus CHIKV-Delta5nsP3
MY193736A (en) 2017-11-03 2022-10-27 Takeda Vaccines Inc Method for inactivating zika virus and for determining the completeness of inactivation
JP7443233B2 (ja) 2017-11-30 2024-03-05 タケダ ワクチン，インコーポレイテッド ジカウイルスを不活性化する方法及び関連する方法
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
WO2020045368A1 (ja) * 2018-08-27 2020-03-05 マイキャン・テクノロジーズ株式会社 不死化単球細胞および誘導細胞を用いた抗感染症薬，ワクチンなどの評価方法
GB2592769B (en) 2020-03-01 2022-05-04 Valneva Austria Gmbh CpG-Adjuvanted SARS-CoV-2 virus vaccine
EP3895729A1 (de) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanter sars-cov-2-virus-impfstoff
TW202203967A (zh) 2020-04-06 2022-02-01 奧地利商瓦爾尼瓦奧地利有限責任公司 不活化ＳＡＲＳ—ＣｏＶ—２病毒疫苗
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (de) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Lebender Impfstoff gegen Getah Virus infektiöse Krankheiten, und dreiwertiger lebender Impfstoff gegen japanische Enkephalitis Virus, Schweinparvovirus und Getah Virus
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
DE122009000037I1 (de) 2009-11-05
CN1272879A (zh) 2000-11-08
FR09C0037I1 (de) 2009-09-25
JP2001514844A (ja) 2001-09-18
NZ503522A (en) 2001-06-29
JP4161017B2 (ja) 2008-10-08
DE69837211D1 (de) 2007-04-12
EP1604685A3 (de) 2006-07-05
CA2301000C (en) 2003-07-08
FR09C0037I2 (fr) 2021-11-05
AU748730B2 (en) 2002-06-13
NL300391I1 (nl) 2009-08-03
US6309650B1 (en) 2001-10-30
KR19990023955A (ko) 1999-03-25
EP1604685B1 (de) 2012-02-22
DK1604685T3 (da) 2012-06-18
DE69837211T2 (de) 2007-12-06
ES2382946T3 (es) 2012-06-14
DK1025209T3 (da) 2007-06-25
MY129773A (en) 2007-04-30
WO1999011762A1 (en) 1999-03-11
EP1025209B1 (de) 2007-02-28
AU9004798A (en) 1999-03-22
ES2281929T3 (es) 2007-10-01
KR100314404B1 (ko) 2002-10-12
CA2301000A1 (en) 1999-03-11
EP1604685A2 (de) 2005-12-14
EP1025209A1 (de) 2000-08-09
CN1142271C (zh) 2004-03-17
NL300391I2 (nl) 2009-11-02

Similar Documents

Publication Publication Date Title
DE122009000037I2 (de) Ein an vero-zellen angepasstes abgeschwächtes japanisches enzephalitis virus und ein impfstoff gegen japanische enzephalitis
ATE272640T1 (de) Cyclische sulfonderivate
DE69803199D1 (de) Erkennung und entfernung von makroviren
DE69922857D1 (de) Rechnersicherheit durch Virusuntersuchung
DE69827307D1 (de) Turbolader
DE69809393T2 (de) Gasabsorption
DE69822808D1 (de) Strömungsmaschine
DE69819387D1 (de) Kehlkopfmaske
DE69815569D1 (de) Kehlkopfmaske
DE59811621D1 (de) Blindniet
DK0898969T3 (da) Neospora-vaccine
IS1780B (is) théttilok fyrir gashylki
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
DE69805925D1 (de) Dokumentenzuführgerät
DE69801856D1 (de) Befestigungselement
DE19881472D2 (de) Gassack
DE59801415D1 (de) Gassack
ATE345815T1 (de) Kombinierte impfstoffe gegen hepatitis a und hepatitis b
DE19880533T1 (de) Spektralanalyse
DK0891803T3 (da) Gastørreanordning
DE59810338D1 (de) Gassack
FR2769951B1 (fr) Turbocompresseur
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
DE59812220D1 (de) Halte- und trageband
FI944558A0 (fi) Virus